inPractice® - ACTG 5202 Trial

Special Considerations in the Management of HIV-Infected Patients From Minority Communities

Authors: Bisola Ojikutu, MD, MPH; Valerie E. Stone, MD, MPH (More Info)
Section Editor: Judith S. Currier, MD, MSc
Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
Last Reviewed: 7/9/18 (What's New)

Summary

Study ACTG 5202 compared atazanavir/ritonavir or efavirenz with either emtricitabine/tenofovir DF or abacavir/lamivudine in treatment-naive patients^{[Smith 2014]}
Of enrollees, 33% of participants were non-Hispanic blacks and 23% were Hispanic
Black race was associated with greater likelihood of virologic failure across all treatment regimens

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Initial Antiretroviral Therapy, Minority-Ethnic Communities, Pharmacokinetics, Special Populations